On August 25, 2026, REGENXBIO Inc.'s Board elected Gregory Ciongoli as a Class II director and appointed him to the Audit and Nominating committees. Concurrently, directors Jean Bennett and A.N. "Jerry" Karabelas resigned from the Board but will serve as advisors until February 2027. The Board reduced its size to nine members. Mr. Ciongoli received an initial equity award valued at $550,000 comprising stock options with a $8.91 exercise price and restricted stock units, along with annual retainers totaling $60,000. REGENXBIO is a biotechnology company focused on developing AAV gene therapies for rare and retinal diseases.

REGENXBIO Inc. announced that the FDA placed a clinical hold on its Investigational New Drug application for RGX-121, an investigational gene therapy for Mucopolysaccharidosis type II (MPS II). The hold follows asymptomatic spine MRI findings in five participants of the CAMPSIITE study. REGENXBIO does not expect to resubmit the Biologics License Application for RGX-121 in the near term. The company stated that patients remain clinically stable and attributed potential findings to the disease itself rather than the therapy. This regulatory setback impacts the MPS II program, though the firm maintains its pipeline focus on Duchenne muscular dystrophy and wet AMD candidates. REGENXBIO Inc. is a biotechnology company developing AAV gene therapies for rare and retinal diseases.

REGENXBIO Inc. reported second quarter 2026 financial results and operational highlights for the period ended June 30, 2026. The company achieved net income of $22.7 million, or $0.43 per share, compared to a net loss of $70.9 million in the prior year period. Revenues increased to $108.0 million from $21.4 million, driven by a $100.0 million development milestone payment from AbbVie for dosing the first patient in the NAAVIGATE diabetic retinopathy study. The company received over $200 million in new capital in July 2026, including approximately $108 million in net proceeds from an underwritten public offering and the AbbVie milestone payment, extending its cash runway into Q4 2027. Key clinical updates include the Phase III AFFINITY DUCHENNE trial meeting its primary endpoint with high statistical significance (p<0.0001) and a BLA submission for RGX-202 on track for Q3 2026 initiation. REGENXBIO is a biotechnology company focused on developing AAV gene therapies for rare, retinal, neuromuscular, and neurodegenerative diseases.

REGENXBIO Inc. entered into an underwriting agreement on July 16, 2026, to offer and sale of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The underwriters, including Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives, exercised an option to purchase an additional 1,667,250 shares of common stock. The net proceeds from the offering, including the exercise of the option, are expected to be approximately $107.8 million. REGENXBIO is a biotechnology company focused on gene therapy development for rare and retinal diseases.

REGENXBIO Inc. announced on June 29, 2026, that it earned a $100.0 million milestone payment from AbbVie Global Enterprises Ltd. This payment stems from a Collaboration and License Agreement and is triggered by the dosing of the first patient in the Phase IIb/III clinical trial of surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The company expects to receive the funds in July 2026. REGENXBIO Inc. is a biotechnology company focused on developing gene therapies.